ABIONYX Pharma

Report Publication Announcement • Jan 13, 2025

ABIONYX Pharma announces its financial calendar for the year 2025

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 13th, 2025, 6:00 pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, today announces its financial calendar for 2025.

Events	Dates*
Cash position and activity update for Q4 2024	Thursday, February 27, 2025
2024 Full-Year Results	Thursday, March 6, 2025
Cash position and activity update for Q1 2025	Wednesday, May 28, 2025
Cash position and activity update for Q2 2025	Thursday, August 28, 2025
2025 Half-Year Results	Thursday, September 25, 2025
Cash position and activity update for Q3 2025	Tuesday, November 25, 2025

* indicative dates subject to change

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.

Contacts:

NewCap	NewCap
Investor relations	Media relations
Nicolas Fossiez	Arthur Rouillé
Louis-Victor Delouvrier	abionyx@newcap.eu
abionyx@newcap.eu	+33 (0)1 44 71 00 15
+33 (0)1 44 71 98 53